Studies have demonstrated that IGF-1R overexpression was associated with disease progression, poor prognosis, and treatment resistance in breast cancer, esophageal adenocarcinoma, colorectal cancer, and squamous cell carcinoma [53]. This evidence concerns the gene IGF1R and colorectal cancer.